Literature DB >> 25154480

[Organ-preserving therapy for penile carcinoma].

O W Hakenberg1, C Protzel.   

Abstract

In recent years, a definite change towards organ-sparing, reconstructive local treatment of penile cancer has been observed. Surgical treatment aims to achieve margin-free resections with risk-adapted much smaller safety margins. Thus, the penile structures are preserved as far as possible or reconstructed in order to achieve a functionally and cosmetically satisfactory result. The oncological safety concerning tumor-free survival is not compromised. However, a higher rate of local recurrences has to be accepted.

Entities:  

Mesh:

Year:  2014        PMID: 25154480     DOI: 10.1007/s00120-014-3525-1

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  21 in total

1.  Glansectomy with split-thickness skin graft for the treatment of penile carcinoma.

Authors:  G Morelli; R Pagni; C Mariani; G Campo; F Menchini-Fabris; R Minervini; A Minervini
Journal:  Int J Impot Res       Date:  2009-05-21       Impact factor: 2.896

Review 2.  Penile cancer and phallus preservation strategies: a review of current literature.

Authors:  Marianna Zukiwskyj; Padraig Daly; Eric Chung
Journal:  BJU Int       Date:  2013-11       Impact factor: 5.588

3.  Glans resurfacing for the treatment of carcinoma in situ of the penis: surgical technique and outcomes.

Authors:  Majid Shabbir; Asif Muneer; Jas Kalsi; Chitranjan J Shukla; Evangelos Zacharakis; Giulio Garaffa; David Ralph; Suks Minhas
Journal:  Eur Urol       Date:  2010-10-20       Impact factor: 20.096

4.  Presence of high-risk human papillomavirus DNA in penile carcinoma predicts favorable outcome in survival.

Authors:  Anne P Lont; Bin K Kroon; Simon Horenblas; Maarten P W Gallee; Johannes Berkhof; Chris J L M Meijer; Peter J F Snijders
Journal:  Int J Cancer       Date:  2006-09-01       Impact factor: 7.396

5.  What surgical resection margins are required to achieve oncological control in men with primary penile cancer?

Authors:  Suks Minhas; Oliver Kayes; Paul Hegarty; Pardeep Kumar; Alex Freeman; David Ralph
Journal:  BJU Int       Date:  2005-11       Impact factor: 5.588

6.  Total phallic reconstruction after penile amputation for carcinoma.

Authors:  Giulio Garaffa; Amr A Raheem; Nim A Christopher; David J Ralph
Journal:  BJU Int       Date:  2009-02-23       Impact factor: 5.588

Review 7.  Lymphadenectomy in the surgical management of penile cancer.

Authors:  Chris Protzel; Antonio Alcaraz; Simon Horenblas; Giorgio Pizzocaro; Alexandre Zlotta; Oliver W Hakenberg
Journal:  Eur Urol       Date:  2009-02-23       Impact factor: 20.096

8.  Association of hypospadias with hypoplastic synpolydactyly and role of HOXD13 gene mutations.

Authors:  Emre Tüzel; Hale Samli; Ilhami Kuru; Seval Türkmen; Yavuz Demir; Gökhan Maralcan; Cem Güler
Journal:  Urology       Date:  2007-07       Impact factor: 2.649

9.  HPV infection and immunochemical detection of cell-cycle markers in verrucous carcinoma of the penis.

Authors:  Elzbieta Stankiewicz; Sakunthala C Kudahetti; David M Prowse; Elena Ktori; Jack Cuzick; Laurence Ambroisine; Xiaoxi Zhang; Nicholas Watkin; Catherine Corbishley; Daniel M Berney
Journal:  Mod Pathol       Date:  2009-05-22       Impact factor: 7.842

10.  Sexual outcomes after organ potency-sparing surgery and glans reconstruction in patients with penile carcinoma.

Authors:  Gaetano Gulino; Francesco Sasso; Giuseppe Palermo; Alfonso D'Onofrio; Marco Racioppi; Emilio Sacco; Francesco Pinto; Michele Antonucci; Alessandro D'Addessi; Pierfrancesco Bassi
Journal:  Indian J Urol       Date:  2013-04
View more
  2 in total

1.  [Urethral centralization and pseudo-glans formation after partial penectomy].

Authors:  J Kranz; A Parnham; M Albersen; V Sahdev; M Ziada; R Nigam; A Muneer; J Steffens; P Malone
Journal:  Urologe A       Date:  2017-10       Impact factor: 0.639

Review 2.  [Reconstructive surgery in penile cancer].

Authors:  M Sohn; M Dietrich; A Wirthmann; U M Rieger
Journal:  Urologe A       Date:  2018-04       Impact factor: 0.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.